MAP2K7 and glioma: Fig 2A shows the dose response curves of our NF1 glioma lines to single agent MEK or PI3K inhibition (72h treatment). IC50s varied between 688 and 2412nM for GDC-0941. The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines and is 97nM for the human serum grown TM-31 line (Fig 2B). Fig 2C shows that at the concentrations used we have near full inhibition of pERK (as a readout of MEK inhibition) and pAKT (as a readout for PI3K inhibition).